🔴 Lipocine is trading 5.29% down today amid broad market weakness

Lipocine is trading at $2.15, with a -5.29% change amid a broader risk-off session.

• The S&P 500 is down 0.73%, while the Nasdaq Composite is down 0.93%.
• The company announced initiation of the BLOOM Phase 3 study for postpartum depression, targeting approximately 120 participants, with first dosing expected in early Q4 2026.
• The announcement did not identify a stock-price catalyst or financing transaction; trading activity and volume details were unavailable.